Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.

[1]  M. Esteller,et al.  Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Y. Ba,et al.  MGMT in colorectal cancer: a promising component of personalized treatment , 2016, Tumor Biology.

[3]  C. Cordon-Cardo,et al.  Immunopathologic Assessment of PTEN Expression. , 2016, Methods in molecular biology.

[4]  F. D. De Braud,et al.  Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer , 2016, Targeted Oncology.

[5]  M. Esteller,et al.  Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. J. van den Oord,et al.  MGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma , 2015, International journal of cancer.

[7]  C. Marquette,et al.  Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  N. Ishii,et al.  Immunohistochemical evaluation of O6‐methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma , 2014, Neuropathology : official journal of the Japanese Society of Neuropathology.

[9]  M. Gariboldi,et al.  Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Jerry J. Lou,et al.  Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. , 2013, Neuro-oncology.

[11]  E. Sausville,et al.  A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O6-Methylguanine-DNA Methyltransferase Promoter , 2013, Molecular Cancer Therapeutics.

[12]  M. Esteller,et al.  Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer , 2013, Clinical Cancer Research.

[13]  Takashi Hirai,et al.  Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. , 2011, The American journal of pathology.

[14]  Shuji Ogino,et al.  MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers , 2011, Cancer Causes & Control.

[15]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[16]  Gary L Rosner,et al.  Tumour vasculature: On the verge of collapse , 2005, Nature Reviews Cancer.

[17]  T. Mukai,et al.  The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. , 2005, Journal of biochemistry.

[18]  J. Herman,et al.  Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer , 2004, Oncogene.

[19]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[20]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. , 2000, Cancer research.